DDIT3 and diffuse large B-cell lymphoma: For patients with DLBCL, 5-year PFS rates for the three most common frontline regimens ranged from 44.9% to 56.2%, with a median PFS of 7.7 years (95% CI, 5.8 to not estimable (n.e.); n = 948) for patients receiving R-CHOP (Table 4).